Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Haidar, Ghady ^a   Clancy, Cornelius J ^a,b,c   Chen, Liang ^d   Samanta, Palash ^a   Shields, Ryan K ^a,b,c   Kreiswirth, Barry N ^d   Nguyen, M Hong ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Ceftazidime avibactam; CRE; Drug resistance mechanisms; Enterobacteriaceae; Imipenem relabactam; KPC; Mechanisms of resistance; Porins

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE IMP-1; CARBAPENEMASE; CEFTAZIDIME; IMIPENEM; MK-7655; OMPK36 PROTEIN, KLEBSIELLA PNEUMONIAE; PORIN; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAM ANTIBIOTIC; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM PLUS RELEBACTAM; METALLO BETA LACTAMASE; RELEBACTAM; UNCLASSIFIED DRUG;

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATION; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; KLEBSIELLA OXYTOCA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; WHOLE GENOME SEQUENCING;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMIPENEM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PORINS;

EID: 85028404107     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1074/jbc.M117.794248     Document Type: Article

References (30)

1. Haidar G, Alkroud A, Cheng S, Churilla TM, Churilla BM, Shields RK, Doi Y, Clancy CJ, Nguyen MH. 2016. Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and extended-spectrum-beta-lactamase-producing Enterobacter species. Antimicrob Agents Chemother 60:5208–5214. https://doi.org/10.1128/AAC.00869-16.
2. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58: 4443– 4451. https://doi.org/10.1128/AAC.00099-14.
3. Jacoby GA. 2009. AmpC beta-lactamases. Clin Microbiol Rev 22:161–182. https://doi.org/10.1128/CMR.00036-08.
4. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686. https://doi.org/10.1128/CMR.18.4.657-686.2005.
5. Szabo D, Silveira F, Hujer AM, Bonomo RA, Hujer KM, Marsh JW, Bethel CR, Doi Y, Deeley K, Paterson DL. 2006. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 50: 2833–2835. https://doi.org/10.1128/AAC.01591-05.
6. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. 2015. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13:42–51. https://doi.org/10.1038/nrmicro3380.
7. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 57:2147–2153. https://doi.org/10.1128/AAC.02411-12.
8. Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG. 2016. Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM global surveillance study, 2012 to 2014. Antimicrob Agents Chemother 60:4677– 4683. https://doi.org/10.1128/AAC.02841-15.
9. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem 288:27960–27971. https://doi.org/10.1074/jbc.M113.485979.
10. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390 –394. https://doi.org/10.1128/AAC.00756-10.
11. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
12. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605– 6607. https://doi.org/10.1128/AAC.01165-15.
13. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. 2017. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 61:e02534-16. https://doi.org/10.1128/AAC.02534-16.
14. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
15. Humphries RM, Hemarajata P. 2017. Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother 61:e00537-17. https://doi.org/10 .1128/AAC.00537-17.
16. Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. 2016. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234–6243. https://doi.org/10.1128/AAC.00633-16.
17. Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF. 2017. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015: results from the SMART global surveillance program. Diagn Microbiol Infect Dis 88:171–176. https://doi.org/10.1016/j.diagmicrobio.2017.02.018.
18. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290. https://doi.org/10.1093/jac/dkt178.
19. Bush K. 2015. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483–493. https://doi.org/10.1016/j.ijantimicag.2015.08.011.
20. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029–5031. https://doi.org/10.1128/AAC.00830-15.
21. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258–5265. https://doi.org/10.1128/AAC.01069-13.
22. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. In vitro selection of meropenem resistance among ceftazidime-avibactam resistant, meropenem susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 61:e00079-17. https://doi.org/10.1128/AAC.00079-17.
23. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606. https://doi.org/10.1093/jac/dks121.
24. Pages JM, James CE, Winterhalter M. 2008. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6:893–903. https://doi.org/10.1038/nrmicro1994.
25. Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH. 2015. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 59:5793–5797. https://doi.org/10.1128/AAC.00548-15.
26. Clancy CJ, Hao B, Shields RK, Chen L, Perlin DS, Kreiswirth BN, Nguyen MH. 2014. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother 58:3521–3525. https://doi.org/10.1128/AAC.01949-13.
27. Chavda KD, Chen L, Fouts DE, Sutton G, Brinkac L, Jenkins SG, Bonomo RA, Adams MD, Kreiswirth BN. 2016. Comprehensive genome analysis of carbapenemase-producing Enterobacter spp.: new insights into phylogeny, population structure, and resistance mechanisms. mBio 7:e02093 -16. https://doi.org/10.1128/mBio.02093-16.
28. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement (M100-S25). Clinical and Laboratory Standards Institute, Wayne, PA.
29. Centers for Disease Control and Prevention. Accessed January 26, 2017. FAQs about choosing and implementing a CRE definition. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/hai/organisms/cre/definition.html.
30. Lynch T, Chen L, Peirano G, Gregson DB, Church DL, Conly J, Kreiswirth BN, Pitout JD. 2016. Molecular evolution of a Klebsiella pneumoniae ST278 isolate harboring blaNDM-7 and involved in nosocomial transmission. J Infect Dis 214:798–806. https://doi.org/10.1093/infdis/jiw240.